Spero Therapeutics (SPRO) Other Non Operating Income (2016 - 2026)
Spero Therapeutics posted quarterly Other Non Operating Income of -$1000.0 for Q1 2026, down 200.0% year-on-year from $1000.0 in Q1 2025, and down 150.0% on a QoQ basis from $2000.0 in Q3 2025.
Spero Therapeutics (SPRO) has 11 years of Other Non Operating Income data on file, last reported at -$1000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income fell 200.0% year-over-year to -$1000.0; the trailing twelve-month figure through Mar 2026 stood at $5000.0 (down 93.33% YoY), and the FY2025 full-year result was $7000.0, down 88.33% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$1000.0, down from $2000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $995000.0 in Q2 2022 and bottomed at -$193000.0 in Q1 2022.
- The 5-year median for Other Non Operating Income is $0.0 (2024), against an average of $60687.5.
- Peak annual rise in Other Non Operating Income reached 3200.0% in 2024, while the deepest fall reached 600.0% in 2024.
- A 5-year view of Other Non Operating Income shows it stood at $141000.0 in 2022, then sank by 97.87% to $3000.0 in 2023, then jumped by 3200.0% to $99000.0 in 2024, then tumbled by 97.98% to $2000.0 in 2025, then sank by 150.0% to -$1000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$1000.0 (Q1 2026), $2000.0 (Q3 2025), and $4000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 99,000.00 |
| Sep 30, 2024 | -26,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | -14,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | -10,000.00 |
| Jun 30, 2023 | -6,000.00 |
| Mar 31, 2023 | -2,000.00 |
| Dec 31, 2022 | 141,000.00 |
| Sep 30, 2022 | -23,000.00 |
| Jun 30, 2022 | 995,000.00 |
| Mar 31, 2022 | -193,000.00 |
| Dec 31, 2021 | 204,000.00 |
| Mar 31, 2021 | -118,000.00 |
| Dec 31, 2020 | 162,000.00 |
| Sep 30, 2020 | 55,000.00 |
| Jun 30, 2020 | 889,000.00 |
| Mar 31, 2020 | -674,000.00 |
| Dec 31, 2019 | 354,000.00 |
| Sep 30, 2019 | -135,000.00 |
| Jun 30, 2019 | 135,000.00 |
| Mar 31, 2019 | 385,000.00 |
| Dec 31, 2018 | -616,000.00 |
| Sep 30, 2018 | 472,000.00 |
| Jun 30, 2018 | 15,000.00 |
| Mar 31, 2018 | 172,000.00 |
| Dec 31, 2017 | 132,000.00 |
| Sep 30, 2017 | 122,000.00 |
| Jun 30, 2017 | 402,000.00 |
| Mar 31, 2017 | 1.19 Mn |
| Dec 31, 2016 | 613,000.00 |
| Sep 30, 2016 | -4,000.00 |